We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc.
GMED 71.07+0.5%Jul 12 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jmhollen who wrote (271)7/27/2005 2:46:56 PM
From: Tadsamillionaire  Read Replies (1) of 347
GenoMed Submits 50th Provisional Patent
ST. LOUIS, July 26 /PRNewswire-FirstCall/ -- GenoMed Inc. ('the Company' or 'GenoMed') (Pink Sheets: GMED) announced today that the Company has submitted its 50th provisional patent application, a major milestone in any development stage company. GenoMed has so far been awarded two patents, one for treating acute kidney failure without dialysis, and another for hastening lung maturation in prematurely born infants.

Two of the most recently submitted patent applications include a drug delivery system whereby the delivery of drugs to the bloodstream is controlled through specially formulated toothpastes, and a method to reduce scarring and fibrosis both on the skin and in internal organs.

Small proteins like insulin don't survive the strong acid environment of the stomach, and must be injected to get into the bloodstream. As a result, patients with diabetes have to inject themselves under the skin one to three times a day. Putting insulin in toothpaste may be an effective method to get insulin into the bloodstream directly, especially after flossing, which often causes bleeding of the gums. It may be especially useful for patients with juvenile-onset diabetes, who must begin injecting insulin as pre-teens.

GenoMed's method to reduce scarring, both on the skin and in internal organs, involves another novel use for angiotensin I-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) either as pills, which already exist, or as topical creams. This approach may be useful in dermatology and plastic surgery, especially for burn victims who get extensive scarring, patients with keloid scars, etc.

GenoMed is currently looking for partners to help develop its toothpaste drug delivery system, as well as patients with scars or fibrosis of internal organs for clinical trials. Please contact GenoMed's CEO and Chief Medical Officer, David Moskowitz MD, at
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext